Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of Cabergoline for OHSS Prevention in ICSI
NCT02620605Phase 3Unknown
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabergoline in ovarian hyperstimulation syndrome (OHSS). Status: unknown.
02
Drugs
cabergoline
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT02620605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620605.